Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

RU58841 treatment for hair loss, comparing premixed solutions to powder form. Users prefer powder for cost-effectiveness and customization.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

A user made a 60ml bottle of topical finasteride and noticed faster evaporation due to ethanol, affecting concentration. Suggestions included adjusting the finasteride concentration and application method to minimize ethanol evaporation.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

The conversation discusses hair loss treatments, specifically using 2.5mg dutasteride, minoxidil, and sometimes RU58841, with a focus on diffuse thinning versus recession. It also touches on the impact of estrogen levels on hair density.

A user is concerned about using Alpicort, which contains Prednisolone and Salicylic Acid, for male pattern baldness. They are unsure if it will help or worsen their condition and are seeking advice.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

A female user is using a 5% RU58841 solution with 5 sprays daily and is concerned about potential reactions and the impact of wearing a bonnet. A male user mentioned using 1ml of the same solution daily via dropper.

Mixing topical finasteride with propylene glycol to achieve a specific concentration for scalp application. Calculations for diluting finasteride with minoxidil are also discussed.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Mixing topical finasteride and RU58841 is discussed, with both solutions using isopropyl alcohol and propylene glycol. The user seeks advice on combining these treatments to ensure effectiveness.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.